No Data
No Data
CCORF Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $385
Alnylam Pharmaceuticals: Balancing Promising Pipeline With Competitive Challenges and Strategic Uncertainties
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $371
Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $300
Unlock the Full List